Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.9 USD | -2.48% | +10.07% | -2.80% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 121 and 67.22 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.80% | 1.82B | C- | ||
+24.17% | 556B | B | ||
-6.33% | 354B | C+ | ||
+19.90% | 331B | B- | ||
+7.95% | 296B | C+ | ||
+13.45% | 233B | B+ | ||
+6.04% | 201B | B- | ||
-10.51% | 193B | A+ | ||
-12.26% | 143B | C+ | ||
-6.47% | 144B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMRX Stock
- Ratings Amneal Pharmaceuticals, Inc.